Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib

Leuk Lymphoma. 2018 Oct;59(10):2500-2502. doi: 10.1080/10428194.2017.1421759. Epub 2018 Jan 18.

Authors

Ling Cao¹, Liang Piu Koh², Yeh Ching Linn¹

Affiliations

¹ a Haematology Department , Singapore General Hospital , Singapore , Singapore.
² b Hematology-Oncology Department , National University Health System , Singapore , Singapore.

PMID: 29345206
DOI: 10.1080/10428194.2017.1421759

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anemia, Hemolytic, Autoimmune / drug therapy*
Anemia, Hemolytic, Autoimmune / etiology
Antineoplastic Agents / therapeutic use*
Blast Crisis / therapy*
Bortezomib / therapeutic use*
Dasatinib / therapeutic use
Drug Administration Schedule
Female
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
Middle Aged
Transplantation, Homologous / adverse effects
Treatment Outcome

Substances

Antineoplastic Agents
Bortezomib
Dasatinib